{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T18:16:59Z","timestamp":1778437019629,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing upon decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two anti-SARS-CoV-2 polyclonal equine formulations as potential alternative therapy for COVID-19. We immunized two groups of horses with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic (anti-Mix) viral recombinant proteins. Horses reached a maximum anti-viral antibody level at 7\u00a0weeks following priming, and showed no major adverse acute or chronic clinical alterations. Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and then formulated for parenteral use. Both preparations had similar physicochemical and microbiological quality and showed ELISA immunoreactivity towards S1 protein and the receptor binding domain (RBD). The anti-Mix formulation also presented immunoreactivity against N protein. Due to high anti-S1 and anti-RBD antibody content, final products exhibited high in vitro neutralizing capacity of SARS-CoV-2 infection, 80 times higher than a pool of human convalescent plasma. Pre-clinical quality profiles were similar among both products, but clinical efficacy and safety must be tested in clinical trials. The technological strategy we describe here can be adapted by other producers, particularly in low- and middle-income countries.<\/jats:p>","DOI":"10.1038\/s41598-021-89242-z","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:04:16Z","timestamp":1620641056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19"],"prefix":"10.1038","volume":"11","author":[{"given":"Guillermo","family":"Le\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e1ngela","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Arguedas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aar\u00f3n","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Corrales-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-7564","authenticated-orcid":false,"given":"Kenneth","family":"Risner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarthi","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauren","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maykel","family":"Cerdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deibid","family":"Uma\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Moscoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairo","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cecilia","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"89242_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"89242_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"89242_CR3","first-page":"m1256","volume":"368","author":"J Hopkins","year":"2020","unstructured":"Hopkins, J. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 368, m1256 (2020).","journal-title":"BMJ"},{"key":"89242_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","volume":"8","author":"J Phua","year":"2020","unstructured":"Phua, J. et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir. Med. 8, 506\u2013517 (2020).","journal-title":"Lancet Respir. Med."},{"key":"89242_CR5","doi-asserted-by":"crossref","unstructured":"Tortorici, M. A. & Veesler, D. Structural Insights into Coronavirus Entry. Advances in Virus Research 105, (Elsevier Inc., 2019).","DOI":"10.1016\/bs.aivir.2019.08.002"},{"key":"89242_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292 (2020).","journal-title":"Cell"},{"key":"89242_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1537-2995.2005.00179.x","volume":"45","author":"Z Zhang","year":"2005","unstructured":"Zhang, Z. et al. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion 45, 1160\u20131164 (2005).","journal-title":"Transfusion"},{"key":"89242_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.12688\/wellcomeopenres.15990.1","volume":"5","author":"S Ainsworth","year":"2020","unstructured":"Ainsworth, S., Menzies, S. & Pleass, R. J. Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19. Wellcome Open Res. 5, 115 (2020).","journal-title":"Wellcome Open Res."},{"key":"89242_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall, A. & Pirofski, L. A. The convalescent sera option for containing COVID-19. J. Clin. Invest. 130, 1545\u20131548 (2020).","journal-title":"J. Clin. Invest."},{"key":"89242_CR10","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.ebiom.2020.102768","volume":"55","author":"R de Alwis","year":"2020","unstructured":"de Alwis, R., Chen, S., Gan, E. S. & Ooi, E. E. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 55, 102768 (2020).","journal-title":"EBioMedicine"},{"key":"89242_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1088-9","author":"STH Liu","year":"2020","unstructured":"Liu, S. T. H. et al. Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-1088-9 (2020).","journal-title":"Nat. Med."},{"key":"89242_CR12","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. U. S. A. 117, 9490\u20139496 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"89242_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"JY Ahn","year":"2020","unstructured":"Ahn, J. Y. et al. Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci. 35, 2\u20139 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"89242_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 Critically ill patients with COVID-19 with convalescent plasma. JAMA - J. Am. Med. Assoc. 323, 1582\u20131589 (2020).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"89242_CR15","unstructured":"Joyner, M. J. et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. Preprint at medRxiv 2020.07.29.20162917 (2020)."},{"key":"89242_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80\u201390 (2015).","journal-title":"J. Infect. Dis."},{"key":"89242_CR17","first-page":"391","volume":"9","author":"MB Ali","year":"2003","unstructured":"Ali, M. B. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med. J. 9, 391\u2013392 (2003).","journal-title":"Hong Kong Med. J."},{"key":"89242_CR18","first-page":"309","volume":"9","author":"T Burnouf","year":"2003","unstructured":"Burnouf, T. Treatment of severe acute respiratory syndrome. Hong Kong Med. J. 9, 309 (2003).","journal-title":"Hong Kong Med. J."},{"key":"89242_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1089\/vim.2007.0038","volume":"20","author":"D Luo","year":"2007","unstructured":"Luo, D. et al. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab\u2032)2. Viral Immunol. 20, 495\u2013502 (2007).","journal-title":"Viral Immunol."},{"key":"89242_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1745-7254.2005.00210.x","volume":"26","author":"JH Lu","year":"2005","unstructured":"Lu, J. H. et al. Preparation and development of equine hyperimmune globulin F(ab\u2019)2 against severe acute respiratory syndrome coronavirus. Acta Pharmacol. Sin. 26, 1479\u20131484 (2005).","journal-title":"Acta Pharmacol. Sin."},{"key":"89242_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/135965350501000504","volume":"10","author":"X Wang","year":"2005","unstructured":"Wang, X. et al. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody. Antivir. Ther. 10, 681\u2013690 (2005).","journal-title":"Antivir. Ther."},{"key":"89242_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.intimp.2006.10.009","volume":"7","author":"L Zhou","year":"2007","unstructured":"Zhou, L. et al. Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice. Int. Immunopharmacol. 7, 392\u2013400 (2007).","journal-title":"Int. Immunopharmacol."},{"key":"89242_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/vim.2006.0064","volume":"20","author":"G Zhao","year":"2007","unstructured":"Zhao, G. et al. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters. Viral Immunol. 20, 197\u2013205 (2007).","journal-title":"Viral Immunol."},{"key":"89242_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.antiviral.2016.11.016","volume":"137","author":"Y Zhao","year":"2017","unstructured":"Zhao, Y. et al. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antiviral Res. 137, 125\u2013130 (2017).","journal-title":"Antiviral Res."},{"key":"89242_CR25","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.antiviral.2020.104868","volume":"182","author":"X Pan","year":"2020","unstructured":"Pan, X. et al. Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res. 182, 104868 (2020).","journal-title":"Antiviral Res."},{"key":"89242_CR26","first-page":"1","volume":"80","author":"V Zylberman","year":"2020","unstructured":"Zylberman, V. et al. Development of a hyperimmune equine serum therapy for COVID-19 in Argentina. Medicina (B. Aires) 80, 1\u20136 (2020).","journal-title":"Medicina (B. Aires)"},{"key":"89242_CR27","unstructured":"Cunha, L. E. et al. Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers. Preprint at bioRxiv 2020.08.17.254375 (2020)."},{"key":"89242_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.toxicon.2018.06.084","volume":"151","author":"G Le\u00f3n","year":"2018","unstructured":"Le\u00f3n, G. et al. Current technology for the industrial manufacture of snake antivenoms. Toxicon 151, 63\u201373 (2018).","journal-title":"Toxicon"},{"key":"89242_CR29","first-page":"1215","volume":"45","author":"Y Angulo","year":"1997","unstructured":"Angulo, Y., Estrada, R. & Mar\u00eda Guti\u00e9rrez, J. Effects of bleeding in horses inmunized with snake venoms for antivenom production. Rev. Biol. Trop. 45, 1215\u20131221 (1997).","journal-title":"Rev. Biol. Trop."},{"key":"89242_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0041-0101(94)90087-6","volume":"32","author":"G Rojas","year":"1994","unstructured":"Rojas, G., Jim\u00e9nez, J. M. & Guti\u00e9rrez, J. M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 32, 351\u2013363 (1994).","journal-title":"Toxicon"},{"key":"89242_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680\u2013685 (1970).","journal-title":"Nature"},{"key":"89242_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0003-2697(65)90085-0","volume":"12","author":"R Parvin","year":"1965","unstructured":"Parvin, R., Pande, S. V. & Venkitasubramanian, T. A. On the colorimetric biuret method of protein determination. Anal. Biochem. 12, 219\u2013229 (1965).","journal-title":"Anal. Biochem."},{"key":"89242_CR33","unstructured":"USP (United States Pharmacopoeia). USP 37\/NF32. U. S. Pharmacopeial Convention, Rockville, United States. (2014)."},{"key":"89242_CR34","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1021\/ac60151a007","volume":"31","author":"RJ Lacoste","year":"1959","unstructured":"Lacoste, R. J., Venable, S. & Stone, J. C. Modified 4-aminoantipyrine colorimetric method for phenols: application to an acrylic monomer. Anal. Chem. 31, 1246\u20131249 (1959).","journal-title":"Anal. Chem."},{"key":"89242_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.biologicals.2009.02.020","volume":"37","author":"M Herrera","year":"2009","unstructured":"Herrera, M., Meneses, F., Guti\u00e9rrez, J. M. & Le\u00f3n, G. Development and validation of a reverse phase HPLC method for the determination of caprylic acid in formulations of therapeutic immunoglobulins and its application to antivenom production. Biologicals 37, 230\u2013234 (2009).","journal-title":"Biologicals"},{"key":"89242_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.toxicon.2015.08.015","volume":"105","author":"G Solano","year":"2015","unstructured":"Solano, G., G\u00f3mez, A. & Le\u00f3n, G. Assessing endotoxins in equine-derived snake antivenoms: Comparison of the USP pyrogen test and the Limulus Amoebocyte Lysate assay (LAL). Toxicon 105, 13\u201318 (2015).","journal-title":"Toxicon"},{"key":"89242_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2012.09.006","volume":"387","author":"E Corrales-Aguilar","year":"2013","unstructured":"Corrales-Aguilar, E. et al. A novel assay for detecting virus-specific antibodies triggering activation of Fc\u03b3 receptors. J. Immunol. Methods 387, 21\u201335 (2013).","journal-title":"J. Immunol. Methods"},{"key":"89242_CR38","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).","journal-title":"PLoS Biol."},{"key":"89242_CR39","unstructured":"CIOMS. CIOMS International Guiding Principles for Biomedical Research Involving Animals. 12, (1985)."},{"key":"89242_CR40","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894-904.e9 (2020).","journal-title":"Cell"},{"key":"89242_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","volume":"9","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Du, L. & Shi, Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg. Microbes Infect. 9, 275\u2013277 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"89242_CR42","first-page":"e01548","volume":"93","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Equine-origin immunoglobulin fragments protect nonhuman primates from Ebola virus disease. J. Virol. 93, e01548-e1618 (2019).","journal-title":"J. Virol."},{"key":"89242_CR43","doi-asserted-by":"publisher","first-page":"34610","DOI":"10.1074\/jbc.M603275200","volume":"281","author":"WC Hwang","year":"2006","unstructured":"Hwang, W. C. et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J. Biol. Chem. 281, 34610\u201334616 (2006).","journal-title":"J. Biol. Chem."},{"key":"89242_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"89242_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du, L. et al. The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"89242_CR46","doi-asserted-by":"publisher","first-page":"17134","DOI":"10.1074\/jbc.M602107200","volume":"281","author":"IM Yu","year":"2006","unstructured":"Yu, I. M., Oldham, M. L., Zhang, J. & Chen, J. Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between Corona- and Arteriviridae. J. Biol. Chem. 281, 17134\u201317139 (2006).","journal-title":"J. Biol. Chem."},{"key":"89242_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.micinf.2020.05.008","volume":"22","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. Microbes Infect. 22, 206\u2013211 (2020).","journal-title":"Microbes Infect."},{"key":"89242_CR48","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"89242_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"89242_CR50","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/cid\/ciaa310","volume":"71","author":"L Guo","year":"2020","unstructured":"Guo, L. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin. Infect. Dis. 71, 778\u2013785 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"89242_CR51","first-page":"845","volume":"26","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 26, 845\u2013848 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"89242_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KKW To","year":"2020","unstructured":"To, K. K. W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"89242_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"D Schoeman","year":"2019","unstructured":"Schoeman, D. & Fielding, B. C. Coronavirus envelope protein: current knowledge. Virol. J. 16, 1\u201322 (2019).","journal-title":"Virol. J."},{"key":"89242_CR54","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1128\/JVI.01052-08","volume":"82","author":"YL Siu","year":"2008","unstructured":"Siu, Y. L. et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of Virus-Like Particles. J. Virol. 82, 11318\u201311330 (2008).","journal-title":"J. Virol."},{"key":"89242_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2174\/187152811797200605","volume":"10","author":"G Le\u00f3n","year":"2011","unstructured":"Le\u00f3n, G. et al. Immune response towards snake venoms. Inflamm. Allergy Drug Targets 10, 381\u2013398 (2011).","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"89242_CR56","unstructured":"WHO (World Health Organization). WHO Guidelines for the Production , Control and Regulation of Snake Antivenom Immunoglobulins. Annex 5 WHO Technical Report Series, No. 1004. Geneva (2017)."},{"key":"89242_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1371\/journal.pntd.0000767","volume":"4","author":"IS Abubakar","year":"2010","unstructured":"Abubakar, I. S. et al. Randomised controlled double-blind non-inferiority trial of two antivenoms for Saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. PLoS Negl. Trop. Dis. 4, 8\u201317 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"89242_CR58","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0041-0101(98)00220-7","volume":"37","author":"R Otero","year":"1999","unstructured":"Otero, R. et al. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 37, 895\u2013908 (1999).","journal-title":"Toxicon"},{"key":"89242_CR59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.toxicon.2011.11.017","volume":"59","author":"R Otero","year":"2012","unstructured":"Otero, R. et al. Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab\u2019)2] antivenoms, in Bothrops asper bites in Colombia. Toxicon 59, 344\u2013355 (2012).","journal-title":"Toxicon"},{"key":"89242_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biologicals.2007.02.004","volume":"35","author":"M Mpandi","year":"2007","unstructured":"Mpandi, M. et al. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins. Biologicals 35, 335\u2013341 (2007).","journal-title":"Biologicals"},{"key":"89242_CR61","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/btpr.1758","volume":"29","author":"CP Caricati","year":"2013","unstructured":"Caricati, C. P. et al. Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process. Biotechnol. Prog. 29, 972\u2013979 (2013).","journal-title":"Biotechnol. Prog."},{"key":"89242_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.toxicon.2013.09.010","volume":"76","author":"G Le\u00f3n","year":"2013","unstructured":"Le\u00f3n, G. et al. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon 76, 63\u201376 (2013).","journal-title":"Toxicon"},{"key":"89242_CR63","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"89242_CR64","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","volume":"20","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339\u2013341 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"89242_CR65","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","volume":"10","author":"EA Van Erp","year":"2019","unstructured":"Van Erp, E. A., Luytjes, W., Ferwerda, G. & Van Kasteren, P. B. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front. Immunol. 10, 548 (2019).","journal-title":"Front. Immunol."},{"key":"89242_CR66","first-page":"25","volume":"22","author":"MS Yip","year":"2016","unstructured":"Yip, M. S. et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med. J. 22, 25\u201331 (2016).","journal-title":"Hong Kong Med. J."},{"key":"89242_CR67","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","volume":"2","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361\u2013376 (2016).","journal-title":"ACS Infect. Dis."},{"key":"89242_CR68","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1128\/JVI.00671-11","volume":"85","author":"M Jaume","year":"2011","unstructured":"Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc\u03b3R pathway. J. Virol. 85, 10582\u201310597 (2011).","journal-title":"J. Virol."},{"key":"89242_CR69","doi-asserted-by":"publisher","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI insight 4, e123158 (2019).","journal-title":"JCI insight"},{"key":"89242_CR70","doi-asserted-by":"crossref","unstructured":"Quinlan, B. D. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. Prepint at SSRN: https:\/\/ssrn.com\/abstract=3575134 (2020).","DOI":"10.2139\/ssrn.3575134"},{"key":"89242_CR71","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.intimp.2007.09.011","volume":"7","author":"Y Xu","year":"2007","unstructured":"Xu, Y. et al. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab\u2032)2 in macaque. Int. Immunopharmacol. 7, 1834\u20131840 (2007).","journal-title":"Int. Immunopharmacol."},{"key":"89242_CR72","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.toxicon.2009.01.012","volume":"53","author":"A Segura","year":"2009","unstructured":"Segura, A. et al. Stability of equine IgG antivenoms obtained by caprylic acid precipitation: towards a liquid formulation stable at tropical room temperature. Toxicon 53, 609\u2013615 (2009).","journal-title":"Toxicon"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89242-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T10:12:44Z","timestamp":1675246364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89242-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89242"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89242-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9825"}}